Citigroup’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $56.6K | Buy |
8,586
+7,957
| +1,265% | +$54.2K | ﹤0.01% | 4931 |
|
|
2026
Q1 | $4.38K | Buy |
629
+361
| +135% | +$2.8K | ﹤0.01% | 5290 |
|
|
2025
Q4 | $1.89K | Sell |
268
-116
| -30% | -$895 | ﹤0.01% | 5463 |
|
|
2025
Q3 | $2.86K | Sell |
384
-5,553
| -94% | -$42.2K | ﹤0.01% | 5398 |
|
|
2025
Q2 | $43.6K | Buy |
5,937
+1,084
| +22% | +$9.46K | ﹤0.01% | 4839 |
|
|
2025
Q1 | $37.5K | Sell |
4,853
-546
| -10% | -$5.99K | ﹤0.01% | 4957 |
|
|
2024
Q4 | $65.3K | Buy |
5,399
+323
| +6% | +$4.13K | ﹤0.01% | 5007 |
|
|
2024
Q3 | $63.7K | Buy |
5,076
+3,514
| +225% | +$45.3K | ﹤0.01% | 4941 |
|
|
2024
Q2 | $18.6K | Sell |
1,562
-10,606
| -87% | -$146K | ﹤0.01% | 5024 |
|
|
2024
Q1 | $213K | Buy |
12,168
+4,420
| +57% | +$79.7K | ﹤0.01% | 3999 |
|
|
2023
Q4 | $199K | Buy |
+7,748
| New | +$110K | ﹤0.01% | 3924 |
|
|
2022
Q3 | – | Sell |
-67
| Closed | -$1K | – | 6028 |
|
|
2022
Q2 | $1K | Buy |
+67
| New | +$445 | ﹤0.01% | 6027 |
|
|
2021
Q2 | – | Sell |
-649
| Closed | -$25K | – | 6237 |
|
|
2021
Q1 | $25K | Sell |
649
-280
| -30% | -$12.8K | ﹤0.01% | 5106 |
|
|
2020
Q4 | $44K | Buy |
929
+788
| +559% | +$34.1K | ﹤0.01% | 6125 |
|
|
2020
Q3 | $5K | Sell |
141
-165
| -54% | -$6.46K | ﹤0.01% | 7014 |
|
|
2020
Q2 | $13K | Buy |
+306
| New | +$14.4K | ﹤0.01% | 6907 |
|
|
2019
Q4 | – | Sell |
-179
| Closed | -$7K | – | 7723 |
|
|
2019
Q3 | $7K | Sell |
179
-591
| -77% | -$31.9K | ﹤0.01% | 7212 |
|
|
2019
Q2 | $43K | Buy |
770
+378
| +96% | +$23.6K | ﹤0.01% | 6607 |
|
|
2019
Q1 | $24K | Sell |
392
-69
| -15% | -$4.43K | ﹤0.01% | 6855 |
|
|
2018
Q4 | $28K | Buy |
461
+26
| +6% | +$1.92K | ﹤0.01% | 6682 |
|
|
2018
Q3 | $35K | Buy |
435
+118
| +37% | +$9.35K | ﹤0.01% | 6796 |
|
|
2018
Q2 | $28K | Buy |
+317
| New | +$55.6K | ﹤0.01% | 6737 |
|
|
2017
Q1 | – | Sell |
-1
| Closed | – | – | 7244 |
|
|
2016
Q4 | $0 | Buy |
+1
| New | +$90 | ﹤0.01% | 7235 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | – | – | 7564 |
|
|
2015
Q4 | $0 | Buy |
+1
| New | +$393 | ﹤0.01% | 7673 |
|
|
2015
Q1 | – | Sell |
-1
| Closed | -$2K | – | 7279 |
|
|
2014
Q4 | $2K | Buy |
+1
| New | +$1.93K | ﹤0.01% | 6861 |
|
|
2014
Q3 | – | Sell |
-2
| Closed | -$4.95K | – | 6906 |
|
|
2014
Q2 | $5K | Sell |
2
-4
| -67% | -$13.1K | ﹤0.01% | 6457 |
|
|
2014
Q1 | $21K | Sell |
6
-10
| -63% | -$37K | ﹤0.01% | 5990 |
|
|
2013
Q4 | $51K | Buy |
16
+1
| +7% | +$3.94K | ﹤0.01% | 5715 |
|
|
2013
Q3 | $61K | Sell |
15
-1
| -6% | -$4.02K | ﹤0.01% | 5126 |
|
|
2013
Q2 | $53K | Buy |
+16
| New | +$60.9K | ﹤0.01% | 5342 |
|
Other funds holding GYRE
HH
OCA
SS
Citigroup's GYRE Position: Q2 2026 in Review
Citigroup increased its Gyre Therapeutics (GYRE) stake by 1,265% in Q2 2026, buying an estimated $54.2K and bringing the position to 8,586 shares worth $56.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4931.
Citigroup first reported a position in GYRE in Q2 2013 and has held it in 30 quarters since. The position peaked at $213K in Q1 2024. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.
- Citigroup held 8,586 shares of Gyre Therapeutics worth $56.6K as of Q2 2026.
- Citigroup bought 7,957 Gyre Therapeutics shares in Q2 2026, an estimated $54.2K.
- Gyre Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4931 holding.
- Citigroup first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 30 quarters since.
- Citigroup's Gyre Therapeutics position peaked at $213K in Q1 2024.
- 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.